.jpeg/:/rs=w:1240,h:620,cg:true,m/cr=w:1240,h:620)
Retatrutide is a next-generation triple agonist that targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors—three key pathways involved in appetite regulation, energy expenditure, and metabolic function. GLP-1 helps regulate hunger and slow gastric emptying, GIP supports insulin response and nutrient metabolism, and glucagon may play a role in increasing energy expenditure and fat utilization.
By engaging multiple metabolic pathways simultaneously, Retatrutide represents a more advanced and comprehensive approach to weight management. This multi-pathway mechanism may support enhanced appetite control, increased calorie burning, and broader metabolic optimization compared to single- or dual-pathway therapies.
Retatrutide is a next-generation, physician-guided weight loss therapy designed to support appetite control, metabolic function, and energy expenditure through multiple pathways. At I AM Wellness MD, Retatrutide is offered as part of an advanced medical weight loss program for patients seeking a more comprehensive and future-focused approach to weight management.
Retatrutide works by influencing several key processes involved in weight regulation:
✔ Reduces appetite and helps regulate hunger signals
✔ Slows gastric emptying to promote fullness
✔ Supports insulin sensitivity and glucose control
✔ May increase energy expenditure and fat utilization
✔ Supports broader metabolic optimization
This triple-pathway mechanism provides a more comprehensive metabolic approach, which may help support deeper and more sustained weight loss when combined with lifestyle changes and medical guidance.
✔ Enhanced appetite control
✔ Increased metabolic activity
✔ Improved fat utilization
✔ More consistent energy levels
✔ Potential for greater weight loss in some individuals
Individual results vary and are supported through ongoing medical oversight.


While both medications target multiple metabolic pathways, Retatrutide expands on this approach by including a third pathway (glucagon) in addition to GLP-1 and GIP
This triple-pathway mechanism may provide:
✔ Broader metabolic coverage
✔ Increased energy expenditure support
✔ Enhanced fat metabolism
You may be a candidate for Retatrutide if you:
✔ Have a BMI of 30 or higher
✔ Have a BMI of 27+ with weight-related conditions
✔ Have not achieved desired results with other programs
✔ Are seeking a more advanced, next-generation approach
Final eligibility is determined by a licensed provider after medical review.
✔ Weekly self-administered injections
✔ Gradual dose escalation based on tolerance
✔ Ongoing provider support and check-ins
✔ Adjustments based on progress and response
Programs are designed to support long-term metabolic improvement and sustainable results.

Retatrutide is an emerging therapy and may not be appropriate for all patients. It may not be recommended for individuals with certain medical conditions, including a history of specific thyroid cancers or pancreatitis.
All patients are evaluated by a licensed provider before starting treatment to ensure safety and appropriateness.

Retatrutide is offered as part of advanced medical weight loss programs that include:
✔ Physician oversight
✔ Dosing optimization guidance
✔ Ongoing support and monitoring
✔ Personalized care plans
You may also want to explore other medical weight loss programs:
👉 Semaglutide Weight Loss Program